AstraZeneca reports strong growth in 2023 despite COVID-19 challenges
AstraZeneca, a global biopharmaceutical company, announced its financial results for the full year 2023, showing a 6% increase in total revenue and a 15% increase...
Jazz Pharmaceuticals acquires Redx’s KRAS inhibitor program
Alderley Park, UK: Jazz Pharmaceuticals plc and Redx Pharma plc have signed a definitive agreement under which Jazz will acquire Redx’s KRAS (Kirsten rat sarcoma...
AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise oncology treatment
LONDON: AstraZeneca has entered into a new global development and commercialisation agreement with Daiichi Sankyo Company Limited for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen...
Avacta signs collaboration and option agreement with ADC Therapeutics
LONDON: Avacta Group plc, a biotechnology company developing novel cancer immunotherapies based on its proprietary Affimer platform, has entered a collaboration and option agreement with...